Clinical pharmacogenomics for CYP2C8 and CYP2C9: General concepts and application to the use of NSAIDs;Farmacogenómica clínica de CYP2C8 y CYP2C9: Conceptos generales y aplicación al uso de AINE

Farmacia Hospitalaria

Volumn 30, Issue 4, 2006, Pages 240-248

  Martinez C ^a   Blanco, G ^b   Garcia Martin E ^a   G Agúndez, José A ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

CYP2C8; CYP2C9; Metabolism; Phamacogenomics; Pharmacokinetics

Indexed keywords

ACECLOFENAC; AMIODARONE; CELECOXIB; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DICLOFENAC; ENDONUCLEASE; ETOPOSIDE; FLUINDOSTATIN; GLIBENCLAMIDE; IBUPROFEN; INDOMETACIN; IRBESARTAN; LORNOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PARECOXIB; PHENYTOIN; PIROXICAM; TENIPOSIDE; TOLBUTAMIDE; VALDECOXIB; WARFARIN;

ASIAN; CAUCASIAN; DRUG METABOLISM; ENZYME SUBSTRATE; ETHNIC GROUP; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MICROARRAY ANALYSIS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; POPULATION GENETIC PARAMETERS; REVIEW; RISK FACTOR; STOMACH HEMORRHAGE;

EID: 33750150828     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)73982-4     Document Type: Review

References (101)

1. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669-76.
2. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
3. Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005; 59: 62-9.
4. García-Martín E, Martínez C, Tabares B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76: 119-27.
5. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004; 141: 205-8.
6. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a hugenet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
7. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diag Ther 2006; in press.
8. Sim SC, Ingelman-Sundberg M, Daly AK, Nebert DW. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [online]. Available from URL: http: //www.imm.ki.se/CYPalleles/default.htm [Accesed 2006 February 1]. 2006.
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
10. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64: 1579-89.
11. Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002; 17: 374-7.
12. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
13. García-Martín E, Martínez C, Ladero JM, Gamito FJ, Agúndez JA. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9.
14. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004; 76: 113-8.
15. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-7.
16. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-8.
17. King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004; 14: 813-22.
18. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farm FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama 2002; 287: 1690-8.
19. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527-37.
20. Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, et al. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 2004; 50: 141-8.
21. Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, et al. The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005; 18: 1276-81.
22. Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002; 54: 518-21.
23. Oliver DH, Thompson RE, Griffin CA, Eshleman JR. Use of single nucleotide polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis. J Mol Diagn 2000; 2: 202-8.
24. Hiratsuka M, Agatsuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab 1999; 68: 357-62.
25. Hruska MW, Frye RF, Langaee TY. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem 2004; 50: 2392-5.
26. Eriksson S, Berg LM, Wadelius M, Alderbom A. Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol 2002; 1: 49-59.
27. Mas S, Crescenti A, Vidal-Taboada JM, Bergonon S, Cuevillas F, Laso N, et al. Simultaneous genotyping of CYP2C9*2, *3, and 5′ flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur J Clin Pharmacol 2005; 61: 635-41.
28. Li J, Wen SY, Wang R, Chen K, Fang Y, Pei F, et al. Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray. Yao Xue Xue Bao 2005; 40: 695-9.
29. Nakai K, Habano W, Fukushima N, Suwabe A, Moriya S, Osano K, et al. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005; 78: 107-11.
30. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005; 15: 535-46.
31. Pickering JW, McMillin GA, Gedge F, Hill HR, Lyon E. Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array. Am J Pharmacogenomics 2004; 4: 199-207.
32. Wen SY, Wang H, Sun OJ, Wang SQ. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol 2003; 9: 1342-6.
33. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77: 341-52.
34. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
35. Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004; 49: 582-5.
36. Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH Jr, Piergies A, et al. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos 2000; 28: 308-14.
37. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54: 423-9.
38. Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101-54.
39. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54: 33-41.
40. Richardson CJ, Blocka KL, Ross SG, Verbeeck RK. Piroxicam and 5′-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 1987; 32: 89-91.
41. Zhao J, Leemann T, Dayer P. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 1992; 51: 575-81.
42. Hutzler JM, Kolwankar D, Hummel MA, Tracy TS. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 2002; 30: 1194-200.
43. Bort R, Ponsoda X, Carrasco E, Gómez-Lechón MJ, Castell JV. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996; 24: 834-41.
44. Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74: 222-35.
45. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26: 261-6.
46. Duggan DE, Hogans AF, Kwan KC, McMahon FG. The metabolism of indomethacin in man. J Pharmacol Exp Ther 1972; 181: 563-75.
47. Zarza J. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Thromb Haemost 2003; 90: 161-2.
48. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56: 243-51.
49. Kirchheiner J, Tsahuridu M, Jabrane W, Roots I, Brockmoller J. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med 2004; 1: 63-84.
50. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, et al. Role of cyp2c9 and its variants (cyp2c9*3 and cyp2c9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33: 749-53.
51. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol 2005; 59: 14-7.
52. Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996; 49: 305-8.
53. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998; 28: 1-13.
54. King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001; 61: 49-53.
55. Stierlin H, Faigle JW, Sallmann A, Kung W, Richter WJ, Kriemler HP, et al. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. Isolation and identification of principal metabolites. Xenobiotica 1979; 9: 601-10.
56. Bort R, Mace K, Boobis A, Gómez-Lechón MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58: 787-96.
57. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003; 4: 319-29.
58. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, et al. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 2002; 303: 969-78.
59. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42: 283-92.
60. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55: 51-61.
61. Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57: 729-35.
62. Jaggi R, Addison RS, King AR, Suthers BD, Dickinson RG. Conjugation of desmethylnaproxen in the rat-a novel acyl glucuronide-sulfate diconjugate as a major biliary metabolite. Drug Metab Dispos 2002; 30: 161-6.
63. Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51: 1003-8.
64. Karim A, Laurent A, Slater ME, Kuss ME, Qian J, Crosby-Sessoms SL, et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001; 41: 1111-9.
65. Ibrahim A, Karim A, Feldman J, Kharasch E. The influence of parecoxib, a patenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg 2002; 95: 667-73.
66. AmpliChip CYP450 test. Med Lett Drugs Ther 2005; 47: 71-2.
67. Jain KK. Applications of AmpliChip CYP450. Mol Diagn 2005; 9: 119-27.
68. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Jama 2001; 286: 2270-9.
69. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13: 289-95.
70. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 3247-55.
71. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70: 175-82.
72. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
73. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
74. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 2004; 32: 484-9.
75. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, et al. 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055-7.
76. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
77. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104.
78. Hermida J, Zarza J, Alberca I, Montes R, López ML, Molina E, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99: 4237-9.
79. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28: 1303-10.
80. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR, O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352-8.
81. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11: 287-91.
82. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40: 263-81.
83. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74: 186-94.
84. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 2005; 78: 370-7.
85. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) trial. J Hypertens 2002; 20: 2089-93.
86. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-35.
87. Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12: 111-9.
88. Jones BC, Hawksworth G, Home VA, Newlands A, Morsman J, Tute MS, et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Dispos 1996; 24: 260-6.
89. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414-21.
90. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603.
91. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003; 3: 202-14.
92. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13: 473-80.
93. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11: 223-35.
94. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72: 62-75.
95. Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 2005; 78: 362-9.
96. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30: 385-90.
97. Pullar T, Capell HA. Interaction of indomethacin and warfarin. Br Med J (Clin Res Ed) 1982; 284: 198.
98. Chan TY, Lui SF, Chung SY, Luk S, Critchley JA. Adverse interaction between warfarin and indomethacin. Drug Saf 1994; 10: 267-9.
99. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 2003; 58: 791-4.
100. Vianna-Jorge R, Perini JA, Rondinelli E, Suárez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76: 18-26.
101. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26: 16-43.